Ethanol Sclerotherapy for the Management of Craniofacial Venous Malformations: the Interim Results.
10.3348/kjr.2009.10.3.269
- Author:
In Ho LEE
1
;
Keon Ha KIM
;
Pyoung JEON
;
Hong Sik BYUN
;
Hyung Jin KIM
;
Sung Tae KIM
;
Young Wook KIM
;
Dong Ik KIM
;
Joon Young CHOI
Author Information
1. Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea. somatom@skku.edu
- Publication Type:Original Article ; Evaluation Studies
- Keywords:
Ethanol;
Head and Neck;
Sclerotherapy;
Venous malformations
- MeSH:
Adolescent;
Adult;
Aged;
Analgesics/administration & dosage;
Anti-Infective Agents, Local/adverse effects/*therapeutic use;
Child;
Child, Preschool;
Craniofacial Abnormalities/*therapy;
Ethanol/adverse effects/*therapeutic use;
Feasibility Studies;
Female;
Follow-Up Studies;
Humans;
Male;
Middle Aged;
Pain/drug therapy/etiology;
Retrospective Studies;
Sclerosing Solutions/adverse effects/therapeutic use;
Sclerotherapy/adverse effects/*methods;
Treatment Outcome;
Vascular Malformations/*therapy;
Young Adult
- From:Korean Journal of Radiology
2009;10(3):269-276
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: We wanted to evaluate the safety and feasibility of ethanol sclerotherapy for treating craniofacial venous malformations (CVMs). MATERIALS AND METHODS: From May 1998 to April 2007, 87 patients (40 men and 47 women; age range, 2-68 years) with CVMs underwent staged ethanol sclerotherapy (range, 1-21 sessions; median number of sessions, 2) by the direct puncture technique. Clinical follow up (range, 0-120 months; mean follow up, 35 months; median follow up, 28 months) was performed for all the patients. Therapeutic outcomes were established by evaluating the clinical outcome of the signs and symptoms in all patients, as well as the degree of devascularization, which was determined on the follow-up imaging, in 71 patients. RESULTS: A total of 305 procedures with the use of ethanol were performed in 87 patients. Follow-up imaging studies were performed for 71 of 87 patients. Twenty-three (32%) of the 71 patients showed excellent outcomes, 37 patients (52%) showed good outcomes and 11 patients (16%) showed poor outcomes. Ethanol sclerotherapy was considered effective for 60 patients. All the minor complications such as bulla (n = 5) healed with only wound dressing and observation. Any major complication such as skin necrosis did not develop. CONCLUSION: Percutaneous ethanol sclerotherapy is an effective, safe treatment for CVMs.
